Comparative in vivo evaluation of 2 ?Linagliptin 5 mg Tablet formulations.

Not Applicable

• Conditions: Diabetes mellitus due to underlying condition; Diabetes mellitus.

• Registration Number: IRCT20180620040164N38
• Lead Sponsor: Actover Pharmaceutical Co.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 February 2023

Recruitment & Eligibility

• Status: Complete
• Sex: Male
• Target Recruitment: 24

Inclusion Criteria

Healthy subjects (male) between 18 – 45 years of age and Body Mass Index (BMI) between 18.5 and 30 (inclusive), calculated as kg/m2.
Subjects with no significant diseases or clinically significant abnormal findings during screening, medical history, clinical examination and laboratory evaluations.
Subjects with normal vital signs.
Subjects who agree with patient consent form.

Exclusion Criteria

Known hypersensitivity or idiosyncratic reaction to linagliptin or inactive ingredients.
Acute infection within one week preceding first study drug administration.
Subject has a history of severe diseases which have direct impact on the study.
Smoking more than 10 cigarettes per day and could not tolerate cigarette cessation during each clinical period.
Subjects who have used any drug including prescription or Over-The-Counter (OTC) drugs within 14 days prior to the start of the study and might need drug intake during study period.
Subjects who have a history of alcohol or substance abuse within the last 5 years.
Heavy drinker of alcohol, grapefruit juice or caffeinated drinks or who are on special diet (such as vegetarians) or do exertional physical activity.
Subject intends to be hospitalized within 3 months after first study drug administration.
Subjects who, through completion of this study, would have donated more than 500 ml of blood in 7 days.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Peak Plasma Concentration (Cmax). Timepoint: 13 blood samples will be withdrawn pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 and 72 hours after intervention. Method of measurement: Using non-compartmental model of Win-Nonlin Professional software version 3.2.A (Pharsight Corporation, USA).

Secondary Outcome Measures

Name	Time	Method
AUC (Area Under the Concentration-Time Curve). Timepoint: 13 blood samples will be withdrawn pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 and 72 hours after intervention. Method of measurement: Using non-compartmental model of Win-Nonlin Professional software version 3.2.A (Pharsight Corporation, USA).